Inclusion Criteria:  Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III. Original clinical staged as II-IVa (T2N0 is not included)（according to the 8th AJCC edition). No evidence of distant metastasis (M0). Male and no pregnant female. Satisfactory performance status: ECOG (Eastern Cooperative OncologyGroup) scale 0-1. WBC ≥ 4×109 /L and PLT ≥100×109 /L and HGB ≥90 g/L. With normal liver function test (ALT/AST ≤ 2.5×ULN, TBIL≤ 2.0×ULN). With normal renal function test (Creatinine Clearance ≥ 60 ml/min ).  Exclusion Criteria:  Patients have evidence of relapse or distant metastasis. Histologically confirmed keratinizing squamous cell carcinoma (WHO I). Receiving radiotherapy or chemotherapy previously. The presence of uncontrolled life-threatening illness. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Receiving other ways of anti-cancer therapy. Suffered from other malignant tumors (except the cure of basal cell carcinoma or uterine cervical carcinoma in situ) previously.